SOPHiA GENETICS (SOPH) Current Deferred Revenue (2020 - 2025)

SOPHiA GENETICS (SOPH) has 6 years of Current Deferred Revenue data on file, last reported at $16.7 million in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue rose 191.7% year-over-year to $16.7 million; the trailing twelve-month figure through Dec 2025 stood at $16.7 million (up 191.7% YoY), and the FY2025 full-year result was $16.7 million, up 191.7% from the prior year.
• Current Deferred Revenue rose to $16.7 million in Q4 2025, from $10.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $16.7 million in Q4 2025 to a low of $3.4 million in Q4 2022.
• A 5-year average of $7.4 million and a median of $7.7 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue slumped 39.63% in 2024 and soared 191.7% in 2025, its largest moves.
• Tracing SOPH's Current Deferred Revenue over 5 years: stood at $4.1 million in 2021, then dropped by 15.61% to $3.4 million in 2022, then jumped by 176.47% to $9.5 million in 2023, then tumbled by 39.63% to $5.7 million in 2024, then jumped by 191.7% to $16.7 million in 2025.
• Business Quant data shows SOPH's Current Deferred Revenue at $16.7 million in Q4 2025, $10.0 million in Q3 2025, and $9.6 million in Q2 2025.